China Biologic Products Holdings Inc
China Biologic Products — Investor Presentation (February 2010)
28 slides from China Biologic Products's investor presentation, Feb 26, 2010

Slide 1: China Biologic Products, Inc. – March 2010
March 2010 & China Biologic Products, Inc. A profitable, rapidly growing plasma-based biopharmaceutical products company in China

Slide 2: Safe Harbor Statement
@Safe Harbor Statement CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation includes or incorporates by reference statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securitie

Slide 3: What is Plasma
What is Plasma asa 95%) anc patel 13) ec lend cots 8). Rest of Blood Plasma Freeze (-30° C) Others & China Biologic Products, Inc. 3

Slide 4: Largest non-state owned plasma based biopharmaceutical company in China
Largest non-state owned plasma based biopharmaceutical company in China* + Fully integrated biologic products company with plasma collection. research and development, production and commercial operations * Indirect ownership in three of the 32 approved manufacturers in China + Direct, majority or m

Slide 5: Equity Snapshot
— @ 0@ Equity Snapshot NASDAQ Global Market: CBPO Price (02/22/10): $8.87 Market Capitalization: $191 Revenues (TTM): $94.5M Wtd Avg Diluted Shares (09/30/09) 21.6M / Diluted EPS‘ (TTM) $1.08 P/E (TTM) 9.6x Net Income 2009E: $18 -$22M | 1. Excludes $62,281 in non-cash compensation expenses and $15.0

Slide 6: Plasma-Derived Therapeutics
a-Derived Therapeutics A fully integrated plasma-based biopharmaceutical company Strict quality control throughout plasma Ensure product collection, manufacturing, and distribution safety Manufacturing ution (Fractionation) Plasma-derived Therapeutic proteins products with Direct sales to hospitals

Slide 7: Investment Highlights
@ Investment Highlights Blood products are critical and cannot be substituted in the treatment of medical emergencies and some potentially life-threatening diseases + Rising demand for plasma-based products and increasing pharmaceutical spending in China + Leveraging competitive advantages with new

Slide 8: New Mandates Strengthen Market Structure/Drive Consolidation
®Nnew ndates Strengthen Market ure/Drive Consolidation = = — —__ Government Reform of Plasma-based Industry + Reform of plasma collection stations in 2006 + GMP Certification required for plasma collection stations, biopharmaceutical manufacturers + Restriction of imported products due to past outbr

Slide 9: Plasma collected in China (metric tons)
(Metric Tons)| Collected Plasma in China Except Shandong Taibang 97.0% Collected ; Plasma by Plasma stations Shandong Shandong Taibang sourcing from: 3 Taibang 3.0% ‘Sources: Management's estimates and National Institute for & the Control of Pharmaceutical and Biological Products (Metric Tons) Colac

Slide 10: Domestic Market Share
®Dodmestic Market Share Estimated Plasma-Based Products larket Share in China (Jan '10) Plasma collection centers Estimated annual plasma collection volume (MT) CBPO market share based [egg manutactiring on output value: 18.3% Se capacity (MT) 81.7% 1. China Biologic acquired 90% controlling interes

Slide 11: Rapid expansion in China's pharmaceutical market
+ Rapid expansion in China’s pharmaceutical market Pharmaceutical market expected to grow at 20%+ pace annually through 2013 iss Health, Oct 2009) Drivers include higher health standards, aging population, government spending, rising disposable incomes, accelerating urbanization $124 billion healthc

Slide 12: Under Penetrated Market
= @ Under Penetrated Market China’s plasma-based biopharmaceutical industry is at initial stage of development Volume of Plasma Products Used IVIG (Intravenous Albumin Immunoglobulin G) Factor VIL Regions China* 100kg 1kg 0.110 More developed 200-300kg 10kg 41 countries* * Per million population Ran

Slide 13: Product Revenue Mix
roduct Revenue Mix : e = $< Increasing product diversification and growth in higher margin products | rroovers | iste | ad Human Albumin* 42.7% 58.3% 37.9% 19.6% 5.0% 6.4% 3.0% 3.4% Human Immunoglobulin* 5.3% - 4.9% 9.6% 1.2% 2.7% 4. Includes Shandong Taibang and Dalin but excluding Huitian 2. Shand

Slide 14: Products Development Status
Products Development Status Human Prothrombin Complex Concentrate Approved to commence clinical trial (stage 9) Commercial production expected in 2010 Mew Product Pipeline Human Coagulation Factor VIII Approved to commence clinical trial (stage 9) Commercial production expected in 2010 Human Hepatit

Slide 15: Stringent Quality Control
Stringent Quality Control Shandong Taibang is one of first plasma-based manufacturers in China to receive GMP certification (1999); renewed in 2008 + High barrier to entry: as of 1999 GMP certification is no longer granted to new blood products manufacturers + Stricter inspection standards imposed i

Slide 16: Management team
Mr. Chao Ming Zhao, CEO of China Biologic Products '* Over 10 years of experience in finance, accounting and internal control * Certified Accountant in PRC and an international registered internal auditor + MBA in Finance from Chinese University of Hong Kong Mr. Y. Tristan Kuo, CFO of China Biologic

Slide 17: A profitable, rapidly growing plasma-based biopharmaceutical products company in China
&, China Biologic Products, Inc. A profitable, rapidly growing plasma-based biopharmaceutical products company in China

Slide 18: Strong Revenue Growth
Strong Revenue Growth Revenue US $ in Million: ve 100.0 90-100 Revenue from Qianfeng YoY Organic Growth = 41.8% Revenue from Taibang 2009 Guidance Full Year Revenue Range: $90 to $100 million Full Year Net Income Range: $18 to $22 million China Biologic Products, Inc. 48 eee

Slide 19: Attractive Gross Margin
®Attractive Gross Margin & China Biologic Products, Inc. 19

Slide 20: Rising Net Income
Rising Net Income = EPS ‘9mon 2008"* luted $0.07 $0.18 * Based on diluted share count of 21.6 million ‘9mon 2009*** “* Excludes $1.3 million in non-cash compensation expenses “ Excludes $62,281 in non-cash compensation expenses and $15.0 million related to the changes in the fair value of warrants »

Slide 21: Gross Profit and Net Income quarterly and nine months
Gross Profit $20.1 $9.7 $32.7 $22.5 Operating Income $14.0 $7.0 $20.3, $12.8 Net Income $7.1" $4.5? $12.0 $8.2 1. Q3 2008 excludes $7,314 in non-cash compensation expenses and $13.2 milion related to the changes in the fair value of warrants 2. 3 2008 excludes $20,613 in non-cash compensation expens

Slide 22: Balance sheet summary
Cash and cash equivalents 50.3 88 Total Current Assets 87.6 25.2 Total Current Liabilities 60.8 18.9 Total Shareholders’ Equity 50.8 37.8 China Biologic Products, Inc. 22 SS ee

Slide 23: Peer Valuation
@.@ «Peer Valuation Stock Price Company (25/2010) Hualan Biological Engineering 002007.s2 CNY55.23 CNY 1,178 CNY 1.02 [Beijing Tiantan Biological Products 600161.ss CNY 22.43 CNY 0,904 CNY 0.45 {Shanghai RAS Blood Products 00225282 CNY33.70__ CNY 0.481 CNY 1.01 ‘AUD 31.55 AUD 4,778 ‘AUD 1.80 EUR 10.

Slide 24: Largest non-state owned, fully integrated producer of plasma-based products
Largest non-state owned, fully integrated producer of plasma-based biopharmaceutical products in China Rising demand for plasma-based products and increasing pharmaceutical spending in China Leveraging competitive advantages with new acquisitions With plasma supply secure, focus on increasing capaci

Slide 25: Contact
Contact China Biologic Products Inc. CCG Investor Relations Inc. Y. Tristan Kuo, CFO Crocker Coulson, President No.14 East Hushan Road 1325 Avenue of the Americas, Suite 2800 Taian City, Shandong 271000 New York, NY 10019 PRC Tel: 4 (646) 213-1915 Tel: 86 538-6202306 Crocker.Coulson@ccgir.com IR@chi

Slide 26: Overview of SFDA Approval Process for New Plasma Products
Overview of SFDA Approval Process for New Plasma Products Stage Est. Time (Months) 1 Planning stage 1 2 Feasibility study and assumption clarification 2 3. Develop scope and technique for testing the new medicine 6 4 Preparation of a virus inactivation report and submission to the NICPBP for 46 prel

Slide 27: Appendix: Reconciliation of Adjusted Financial Measures
Appendix: Reconciliation of Adjusted Financial Measures Adjusted Net Income ‘Three Months Ended September 30, 2009 ‘Three Months Ended September 30, 2008, Net Income (Loss) Diluted EPS Net Income Diluted EPS Net Income Diluted EPS ‘Adjusted Amount $7,056,078 30.33, $4,499,159 S021 Non-cash employee

Slide 28: Thank you!
March 2010 Cy » China Biologic Products, Inc. A profitable, rapidly growing plasma-based biopharmaceutical products company in. China Thank you!
Source: SEC EDGAR · 8-K filed Feb 26, 2010
More decks from China Biologic Products Holdings Inc
36th Annual J.P. Morgan Healthcare Conference 201837 slides · Jan 8, 2018
35th Annual J.P. Morgan Healthcare Conference 201731 slides · Jan 4, 2017
34th Annual J.P. Morgan Healthcare Conference 201631 slides · Jan 4, 2016
Investor Presentation (June 2012)49 slides · Jun 4, 2012
Investor Presentation (June 2011)28 slides · Jun 7, 2011
Investor Presentation (March 2011)28 slides · Mar 7, 2011